Infoscitex Corporation — Department of Defense SBIR Phase I: There is a substantial clinical need for regenerative therapies that effectively restore f
Infoscitex Corporation — SBIR Phase I award from Department of Defense.
- Amount
- $149,971
- Agency
- Department of Defense · Defense Health Program
- Program / Phase
- SBIR · Phase I
- Solicitation
- 2010.3
- NAICS
- —
- Place of performance
- MA
- Period
- 2011-02-25
Description
There is a substantial clinical need for regenerative therapies that effectively restore function to damaged tissues. For many tissues, autograft remains the clinical standard despite the limited volume available, associated patient morbidity and the resu